Early Clinical Experience with Onasemnogene Abeparvovec in Spinal Muscular Atrophy (SMA) Type 2 Patients at a Single Center

被引：0
|
作者：
Matesanz, Susan
Kichula, Elizabeth
机构：
来源：
NEUROLOGY | 2020年 / 94卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
4855
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Onasemnogene Abeparvovec in Type 1 Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis
    Pascual-Morena, Carlos
    Cavero-Redondo, Ivan
    Luceron-Lucas-Torres, Maribel
    Martinez-Garcia, Irene
    Rodriguez-Gutierrez, Eva
    Martinez-Vizcaino, Vicente
    HUMAN GENE THERAPY, 2023, 34 (3-4) : 129 - 138
  • [32] Acute Benign Myositis Following Onasemnogene Abeparvovec Therapy in Type 1 Spinal Muscular Atrophy
    Dosi, Claudia
    Tozzo, Alessandra
    Masson, Riccardo
    PEDIATRIC NEUROLOGY, 2022, 131 : 23 - 24
  • [33] Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment
    McGrattan, Katlyn E.
    Shell, Richard D.
    Hurst-Davis, Rebecca
    Young, Sally Dunaway
    O'Brien, Eamonn
    Lavrov, Arseniy
    Wallach, Shiri
    LaMarca, Nicole
    Reyna, Sandra P.
    Darras, Basil T.
    JOURNAL OF NEUROMUSCULAR DISEASES, 2023, 10 (04) : 531 - 540
  • [34] Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands
    van der Schans, Simon
    Velikanova, Rimma
    Weidlich, Diana
    Howells, Ruth
    Patel, Anish
    Bischof, Matthias
    Postma, Maarten J.
    Boersma, Cornelis
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2025,
  • [35] Onasemnogene Abeparvovec in Presymptomatic Spinal Muscular Atrophy (SMA): SPRINT Study Update in Children with Three Copies of SMN2
    Strauss, Kevin
    Muntoni, Francesco
    Farrar, Michelle
    Saito, Kayoko
    Mendell, Jerry
    Servais, Laurent
    McMillan, Hugh
    Finkel, Richard
    Swoboda, Kathryn
    Kwon, Jennifer
    Zaidman, Craig
    Chiriboga, Claudia
    Lannaccone, Susan
    Krueger, Jena
    Parsons, Julie
    Shieh, Perry
    Kavanagh, Sarah
    Chand, Deepa
    Tauscher-Wisniewski, Sitra
    McGill, Bryan
    Macek, Thomas
    NEUROLOGY, 2022, 98 (18)
  • [36] Outcomes of Children Treated With Nusinersen/Onasemnogene Abeparvovec for Pediatric Spinal Muscular Atrophy Type 1
    Chacko, A.
    Sly, P. D.
    Gauld, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [37] Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
    Mirea, Andrada
    Shelby, Elena-Silvia
    Axente, Mihaela
    Badina, Mihaela
    Padure, Liliana
    Leanca, Madalina
    Dima, Vlad
    Sporea, Corina
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
  • [38] COST EFFECTIVENESS OF ONASEMNOGENE ABEPARVOVEC IN INFANTS WITH PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY IN ITALY
    Valentini, I
    Ghetti, G.
    Pane, M.
    Cicchetti, A.
    Rumi, F.
    Di Brino, E.
    Basile, M.
    Pistillo, G.
    Bischof, M.
    VALUE IN HEALTH, 2023, 26 (12) : S528 - S529
  • [39] Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec
    Retson, Laura
    Tiwari, Nishant
    Vaughn, Jennifer
    Bernes, Saunder
    Adelson, P. David
    Mansfield, Keith
    Libertini, Silvana
    Kuzmiski, Brent
    Alecu, Iulian
    Gabriel, Richard
    Mangum, Ross
    MOLECULAR THERAPY, 2023, 31 (10) : 2991 - 2998
  • [40] Real-world experience of delivering gene-therapy with onasemnogene abeparvovec (Zolgensma®) for children with spinal muscular atrophy (SMA) type-1 in the UK
    Gowda, V
    Jungbluth, H.
    Standing, E.
    Sheehan, J.
    Hughes, I
    Mccullagh, G.
    Atherton, M.
    Ong, M.
    Majumdar, A.
    Murugan, A.
    Dhawan, A.
    Muntoni, F.
    Baranello, G.
    Scoto, M.
    Manzur, A.
    Munot, P.
    Abbot, L.
    Horrocks, I
    Tirupathi, S.
    Wraige, E.
    NEUROMUSCULAR DISORDERS, 2022, 32
12345